Omeros Corporation (OMER)
7.36
-0.65 (-8.11%)
At close: Apr 03, 2025, 3:59 PM
7.36
0.00%
After-hours: Apr 03, 2025, 04:07 PM EDT
-8.11% (1D)
| Bid | 7.31 |
| Market Cap | 427.35M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -3.14 |
| PE Ratio (ttm) | -2.34 |
| Forward PE | -4.9 |
| Analyst | Hold |
| Ask | 7.36 |
| Volume | 1,126,325 |
| Avg. Volume (20D) | 554,738 |
| Open | 7.64 |
| Previous Close | 8.01 |
| Day's Range | 6.92 - 7.69 |
| 52-Week Range | 2.97 - 13.60 |
| Beta | 2.35 |
About OMER
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell tr...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 8, 2009
Employees 202
Stock Exchange NASDAQ
Ticker Symbol OMER
Website https://www.omeros.com
Analyst Forecast
According to 4 analyst ratings, the average rating for OMER stock is "Hold." The 12-month stock price forecast is $22.5, which is an increase of 205.71% from the latest price.
Stock Forecasts1 month ago
+3.89%
Omeros shares are trading after the company announ...
Unlock content with
Pro Subscription
3 months ago
+37.27%
Omeros shares are trading higher after the company announced that narsoplimab met its primary trial endpoint and will resubmit its narsoplimab Biologics License Application to the FDA.
